graph Evidence gap map comparisons
atezolizumab based treatmentImmune checkpoint association
atezolizumab plus SoC nivolumab plus ipilimumab
mML - L1 - BRAF mutant 2     
Comparator:  vs placebo plus SoC;   vs ipilimumab alone; 
Risk of bias:  low;   some concerns;   high;  NA;